Testing CRB-701 for throat cancer that returned
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests an investigational drug called CRB-701 to see if it can help people with a certain type of throat cancer that has not responded to standard treatments. The trial compares CRB-701 to a doctor's choice of other available treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of throat cancer called oropharyngeal squamous cell carcinoma (cancer in the tonsils, back of tongue, or soft palate).
- The cancer has spread or came back, and it cannot be cured with standard treatments.
- You have already received, or your cancer came back within 6 months of, treatment with platinum chemotherapy and an immunotherapy drug (PD-1/PD-L1 inhibitor).
- You are either on your second or third line of treatment for advanced disease.
- You are able to care for yourself and do light activity (ECOG score 0 or 1).
- You do not have significant untreated side effects from prior treatments, except hair loss.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether radiation or chemoradiation works well for HPV-positive throat cancer. It may be an option if you have this type of cancer and are getting or have already had surgery.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether adding a type of radiation therapy (SBRT) to chemoimmunotherapy before surgery helps people with advanced mouth or throat cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
Hear when a new Oropharyngeal Carcinoma (OPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.